National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lenvatinib (Lenvima®)

Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.

Rapid Review

Commenced Completed Outcome
 05/05/2015  09/07/2015 Full pharmacoeconomic evaluation recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations. January 2016.